Skip to main content

Table 15 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Switzerland

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

  EQ-5D-3L at 6 months (mean) EQ-5D-3L at 12 months (mean) Difference between 12 and 6 months EQ-5D-3L (95% CI) Effect size (Cohen’s D)a n % reporting 3L score increase
3L-VAS
 Improved 0.92 0.93 0.01 (− 0.03 to 0.05) 0.15 10 30
 No change 0.87 0.81 − 0.06 (− 0.19 to 0.07) − 0.22 25 24
 Worsened 0.85 0.84 − 0.01 (− 0.08 to 0.06) − 0.06 20 15
  EQ-5D-5L at 6 months (mean) EQ-5D-5L at 12 months (mean) Difference between 12 and 6 months EQ-5D-5L (95% CI) Effect size (Cohen’s D) n % reporting 5L score increase
5L-VAS
 Improved 0.90 0.91 0.01 (− 0.02 to 0.04) 0.14 10 30
 No change 0.83 0.81 − 0.02 (− 0.10 to 0.07) − 0.06 25 28
 Worsened 0.84 0.85 0.01 (− 0.06 to 0.08) 0.05 20 20
  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large
\